Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats-Reference-Cited by-同舟云学术

Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats

Published:2019-12-05 Issue:3 Volume:47 Page:422-431
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Rodriguez Ruben¹,Escobedo Benny¹,Lee Andrew Y.¹,Thorwald Max¹,Godoy‐Lugo Jose A.¹,Nakano Daisuke²,Nishiyama Akira²,Parkes David G.³,Ortiz Rudy M.¹^ORCID

Affiliation:

1. Department of Molecular & Cellular Biology University of California Merced Merced CA USA

2. Department of Pharmacology Kagawa University Medical School Kagawa Japan

3. DGP Scientific Inc Del Mar CA USA

Funder

AstraZeneca Canada

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1440-1681.13206

Reference66 articles.

1. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States

2. Chronic kidney disease

3. The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults

4. Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults

5. Weight Loss and the Renin-Angiotensin-Aldosterone System

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin and glucagon receptor polypharmacology in chronic kidney disease;American Journal of Physiology-Endocrinology and Metabolism;2024-06-01

2. Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease;Biomedicines;2024-03-14

3. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes;Cell Metabolism;2023-02

4. Angiotensin receptor blockade with olmesartan alleviates brain pathology in obese OLETF rats;Clinical and Experimental Pharmacology and Physiology;2022-12-04

5. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes;International Urology and Nephrology;2022-08-29